title: Outcomes after radical prostatectomy among men who are candidates for active surveillance: results from the SEARCH database.
abstract: OBJECTIVE
  We sought to evaluate outcomes after radical prostatectomy among men with low-risk prostate cancer who would be candidates for active surveillance.
  
  
  METHODS
  Using the Shared Equal Access Regional Cancer Hospital (SEARCH) database of men treated with radical prostatectomy at multiple equal-access medical centers between 1988 and 2007, 398 of 2062 men (19%) met our criteria for potential active surveillance: clinical stage T1c or T2a, prostate-specific antigen (PSA) <10 ng/mL, Gleason sum ≤6, and no more than 1 or 2 positive cores on at least a sextant biopsy. We examined the risk of adverse pathology, biochemical progression, and PSA doubling time (PSADT) at the time of recurrence. We used a Cox proportional hazards model to determine the significant predictors of PSA progression.
  
  
  RESULTS
  Of the men with low-risk prostate cancer, 85% had organ-confined disease, only 2% had seminal vesicle invasion, and no patient had lymph node metastasis. The 5- and 10 year PSA-free survival rates were 81% (95% CI: 76-86%) and 66% (95% CI: 54-76%). On multivariate analysis, older age (P = .005), Agent Orange exposure (P = .02), and obesity (P = .03) were all significantly associated with biochemical failure. Mean and median PSADT among men who experienced recurrence were 37 and 20 months. Only 3 patients experienced recurrence with PSADT < 9 months.
  
  
  CONCLUSIONS
  Most men with low-risk prostate cancer treated with radical prostatectomy experience long-term PSA control. Those who did experience recurrence often did so with a long PSADT. Consistent with prior SEARCH database reports, older age, Agent Orange exposure, and obesity increased the risk of recurrence.
authors.affiliation: Division of Urology, Department of Surgery, University of California-San Diego, San Diego, CA 92103-8897, USA. ckane@ucsd.edu
authors.forename: Christopher J
authors.initials: CJ
authors.lastname: Kane
authors.forename: Ronald
authors.initials: R
authors.lastname: Im
authors.forename: Christopher L
authors.initials: CL
authors.lastname: Amling
authors.forename: Joseph C
authors.initials: JC
authors.lastname: Presti
authors.forename: William J
authors.initials: WJ
authors.lastname: Aronson
authors.forename: Martha K
authors.initials: MK
authors.lastname: Terris
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Freedland
mesh_terms: D016208:Databases, Factual; D018572:Disease-Free Survival; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000453:epidemiology; D011159:Population Surveillance; D017430:Prostate-Specific Antigen; D011468:Prostatectomy / Q000379:methods; D011471:Prostatic Neoplasms / Q000097:blood / Q000453:epidemiology / Q000601:surgery*; D012189:Retrospective Studies; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D017430:Prostate-Specific Antigen
references.citation: J Urol. 2008 Feb;179(2):523-7; discussion 527-8
references.pmid: 18076952
references.citation: J Urol. 2005 Jun;173(6):1938-42
references.pmid: 15879786
references.citation: JAMA. 2005 May 4;293(17):2095-101
references.pmid: 15870412
references.citation: J Urol. 2008 Nov;180(5):1964-7; discussion 1967-8
references.pmid: 18801515
references.citation: Cancer. 2008 Nov 1;113(9):2464-70
references.pmid: 18666213
references.citation: J Urol. 2008 Dec;180(6):2436-40
references.pmid: 18930486
references.citation: Urology. 2004 Mar;63(3):518-22
references.pmid: 15028449
references.citation: Urology. 2002 Oct;60(4):670-4
references.pmid: 12385931
references.citation: Can J Urol. 2005 Jun;12 Suppl 2:21-4
references.pmid: 16018828
references.citation: J Urol. 2003 Jan;169(1):125-9
references.pmid: 12478119
references.citation: J Urol. 2008 May;179(5):1804-9; discussion 1809-10
references.pmid: 18353398
references.citation: J Clin Oncol. 2004 Feb 1;22(3):446-53
references.pmid: 14691122
references.citation: J Urol. 2003 Sep;170(3):905-8
references.pmid: 12913727
references.citation: Urology. 2008 Apr;71(4):573-7
references.pmid: 18387385
references.citation: Cancer. 2008 Apr 15;112(8):1650-9
references.pmid: 18306379
references.citation: Urol Oncol. 2010 May-Jun;28(3):302-7
references.pmid: 19117774
references.citation: Urology. 2007 Mar;69(3):495-9
references.pmid: 17382152
references.citation: Cancer. 2003 Jan 1;97(1):56-62
references.pmid: 12491505
references.citation: J Urol. 2007 Dec;178(6):2359-64; discussion 2364-5
references.pmid: 17936806
references.citation: J Clin Oncol. 2005 Nov 10;23(32):8146-51
references.pmid: 16278465
references.citation: J Urol. 2009 Apr;181(4):1628-33; discussion 1633-4
references.pmid: 19233388
references.citation: BJU Int. 2009 May;103(9):1168-72
references.pmid: 19298411
references.citation: JAMA. 1999 May 5;281(17):1591-7
references.pmid: 10235151
references.citation: Scand J Urol Nephrol. 2003;37(3):213-7
references.pmid: 12775279
references.citation: Urol Oncol. 2007 Nov-Dec;25(6):505-9
references.pmid: 18047961
references.citation: JAMA. 1994 Feb 2;271(5):368-74
references.pmid: 7506797
references.citation: World J Urol. 2008 Oct;26(5):443-6
references.pmid: 18594827
references.citation: J Natl Cancer Inst. 2005 Sep 7;97(17):1236-7
references.pmid: 16145036
references.citation: Cancer. 2008 Jun 15;112(12):2664-70
references.pmid: 18433013
references.citation: JAMA. 2005 Jul 27;294(4):433-9
references.pmid: 16046649